Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non‐small cell lung cancer

Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non‐small cell lung cancer

Abstract Background Durvalumab consolidation is associated with improved survival following concurrent chemoradiotherapy (CCRT) in patients with stage III non‐small cell lung cancer (NSCLC). Given the heterogeneity of stage III NSCLC patients, in this study we evaluated the efficacy and safety of du...

Full description

Bibliographic Details
Main Authors: Yiqing Huang, Joseph J. Zhao, Yu Yang Soon, Alvin Wong, Folefac Aminkeng, Yvonne Ang, Yugarajah Asokumaran, Jia Li Low, Matilda Lee, Joan R. E. Choo, Gloria Chan, Adrian Kee, Sen Hee Tay, Boon Cher Goh, Ross A. Soo
Format: Article
Language:English
Published: Wiley 2022-11-01
Series:Thoracic Cancer
Subjects:
consolidation
Durvalumab
non‐small cell lung cancer
real‐world
stage III
Online Access:https://doi.org/10.1111/1759-7714.14667

Internet

https://doi.org/10.1111/1759-7714.14667

Similar Items